ROBOSENSE
13.1.2021 20:02:36 CET | Business Wire | Press release
RoboSense officially announced the SOP version of the high-performance, automotive-grade, MEMS solid-state LiDAR RS-LiDAR-M1 at CES 2021. In the past five years of research and development, M1 has gone through dozens of iterations and has been presented at the CES for 4 consecutive years winning two CES Innovation Awards. Since July 2020, M1 has received a number of orders for serial production cars worldwide. It has been delivered to OEM partners in batches in December 2020, becoming the world's first mass-production-ready solid-state automotive LiDAR.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005687/en/
The development process of M1 has been finalized after completing the processes of product requirement definition, components selection, design and development, repeated verification tests and manufacturing. The SOP version’s features include:
- The ranging capability reaches more than 150m for 10% reflectivity targets (with range up to 200 meters for detecting vehicle objects). The average resolution of M1 is 0.2°x0.2° (horizontally and vertically) with an ultra-wide field of view 120°×25° (horizontally and vertically) to create a high resolution of 0.75M pixel points per second.
- The RS-LiDAR-M1 has reduced the minimum detection distance to less than 0.5 meters through upgrading the optical system design and signal processing system.
- RoboSense has innovated the signal processing algorithms and optical system design, which has enabled the M1 to distinguish laser emission signals from ambient lights, without further concern of strong sunlight interference.
- M1 uses the unique technologies to filter laser pulses from other LiDARs to prevent multiple LiDAR crosstalk.
- The SOP version of M1 has reduced the size compared to the last version. Up to now, it is the world’s thinnest automotive LiDAR, with a size of 108mm(Depth) x 110mm(Width) x 45mm(Height) to make the integration into the vehicle body easy.
- Power consumption is reduced to less than 15W.
- M1 provides a series of supporting functions, including OTA firmware updating, blockage detection, smart cleaning, smart heating, performance detection, power management, network management, etc.
- RoboSense strictly abides by the ISO26262 safety standard, and has integrated the fail-safe concept and technology from aerospace and rail transportation systems, achieving all-round monitoring of various system modules such as laser emitter and receiver, MEMS control, point cloud processing and transmitting, etc. Its safety mechanism has covered thousands of failure modes, fully achieving the requirements of ASIL-B and SIL-2.
- RoboSense has adopted VDA6.3 as the basis of project management and control, fully implemented the requirements of IATF16949 quality management system and ISO26262 standard, and has integrated ISO16750 and other automotive-grade reliability specifications, to carry out a series of verification tests on M1, including random mechanical vibration, mechanical shock, splash water, stone impact, high and low temperature storage and operation, solar radiation, EMC, chemical corrosion, salt spray and others. The cumulative test time of all M1 test samples has exceeded 300,000 hours, the longest-running prototype has been in continuous operation for more than 700 days, and the total road test mileage has exceeded 200,000 kilometers.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans. http://robosense.ai/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
